Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease
| Autor: | Robert H. Perry, Elaine K. Perry, Gordon K. Wilcock, Seth Love, Katy A Chalmers, Clive Ballard, Harry V. Vinters |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
Pathology medicine.medical_specialty Neurology Amyloid Plaque Amyloid tau Proteins Neuropathology Pharmacology Article Time Cohort Studies Degenerative disease Alzheimer Disease mental disorders Image Processing Computer-Assisted medicine Humans Phosphorylation Aged Retrospective Studies Cholinesterase Aged 80 and over Amyloid beta-Peptides biology business.industry Brain Neurofibrillary Tangles Middle Aged medicine.disease Immunohistochemistry Up-Regulation Treatment Outcome medicine.anatomical_structure Cerebral cortex biology.protein Female Cholinesterase Inhibitors Neurology (clinical) Animal studies Alzheimer's disease business |
| DOI: | 10.1007/s00415-009-5000-2 |
| Popis: | Cholinesterase inhibitors (ChEIs) are widely used for the symptomatic treatment of Alzheimer's disease (AD). In vitro and in animal studies, ChEIs have been shown to influence the processing of Abeta and the phosphorylation of tau, proteins that are the principal constituents of the plaques and neurofibrillary tangles, respectively, in AD brain. However, little is known about the effects of these drugs on Abeta and tau pathology in AD. Using avidin-biotin immunohistochemistry and computer-assisted image analysis, we compared Abeta and tau loads in the frontal and temporal cortices of 72 brains from matched cohorts of AD patients who had or had not received ChEIs. Patients treated with ChEIs had accumulated significantly more phospho-tau in their cerebral cortex than had untreated patients (P = 0.004). Abeta accumulation was reduced but not significantly. These data raise the possibility that increased tau phosphorylation may influence long-term clinical responsiveness to ChEIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|